The 3rd Annual Global Summit on Genitourinary Malignancies focuses on the clinical and practical changes that will occur over the next five years in prostate cancer, renal cell carcinoma and bladder cancer. The program is formatted to foster discussion and debate on the evolution of treatment approaches to genitourinary malignancies featuring didactic lectures, panel discussions and case presentations over individual patient issues and new approaches designed to overcome these challenges.
Presentations will be given by leading experts in the field of genitourinary malignancies, who will offer further insight during question-and-answer sessions. In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their abstracts at an evening poster reception. The Summit assembles translational researchers, clinical researchers, and key community oncologists to address and discuss the challenges of this rapidly developing area of oncology.
Daniel P. Petrylak, MD, completed his medical degree at Case Western Reserve University School of medicine, and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center and fellowship at Memorial Sloan Kettering Cancer Center. He is currently Director of Genitourinary Oncology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center.
Yale University
New Haven, CT
Charles J. Ryan, MD, is the Director of the Hematology, Oncology, and Transplantation Division in theDepartment of Medicine at the University of Minnesota, Minneapolis. He also serves as the AssociateDirector for Clinical Research in the Masonic Cancer Center and holds the B.J. Kennedy Chair in ClinicalMedical Oncology. He is the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group.
University of Minnesota
Minneapolis, MN
Oliver Sartor, MD, is a medical oncologist with a special focus on prostate cancer over the past 28 years. He is currently the Laborde Professor for Cancer Research, Medical Director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane University School of Medicine in New Orleans, LA. He has published over 350 peer review publications and has over 20,000 citations. He has lectured widely, giving lectures on prostate cancer in 34 countries.
Tulane Medical School
New Orleans, LA
Tulane Cancer Center
New Orleans, LA
Helen Diller Family Chair in Urology University of California, San Francisco
San Francisco, CA
Albert Einstein College of Medicine Montefiore Medical Center
Bronx, NY
UCSF Medical Center
San Francisco, CA
Fred Hutchinson Cancer Research Center University of Washington
Seattle, WA
The University of Texas Southwestern
Medical Center
Dallas, TX
University of Washington
Seattle, WA
University of Texas MD Anderson Cancer Center
Houston, TX
University of California, San Francisco
San Francisco, CA
Yale University
New Haven, CT
University of California, San Francisco
San Francisco, CA
Unviersity of Utah
Salt Lake City, UT
University of Minnesota Masonic Cancer Center
Minneapolis, MN
Stritch School of Medicine, Loyola University
Maywood, IL
Princess Margaret Cancer Center
Toronto, Ontario, Canada
The University of Chicago Medicine
Chicago, IL
Department of Oncology Cumming School of Medicine
University of Calgary
Calgary, Alberta, Canada
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL
University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and Public Health
Madison, WI
Harvard Medical School Dana-Farber Cancer Institute
Boston, MA
Moffitt Cancer Center
Tampa, FL
McMaster University Hamilton,
Ontario, Canada
Medical College of Wisconsin
Milwaukee, WI
Synthorx
La Jolla, CA
Northwestern University Feinberg School of Medicine
Chicago, IL
Arvinas
New Haven, CT
Thomas Jefferson University
Philadelphia, PA
Wayne State University
Detroit, MI
University of Minnesota
Minneapolis, MN
University of British Columbia
Vancouver, British Columbia, Canada
University of Southern California
Los Angeles, CA
5:45 PM Welcome and Introductions
6:00 PM GU Malignancies: Perspectives and a Peer Into the Future
6:30 PM Can We Make Prostate Cancer a Chronic Disease?
6:45 PMCan We Cure Metastatic Renal Cell Carcinoma?
7:00 PM How Do We Integrate New Therapies into the Treatment of Bladder Cancer?
7:15 PM Next Steps for Immunotherapy in GU Malignancies
7:30 PM Using Genomics to Select Patients for Organ Preservation
7:45 PMDiscussion
8:00 PMAdjourn to Welcome Reception
5:45 PM Welcome and Introductions
6:00 PM GU Malignancies: Perspectives and a Peer Into the Future
6:30 PM Can We Make Prostate Cancer a Chronic Disease?
6:45 PMCan We Cure Metastatic Renal Cell Carcinoma?
7:00 PM How Do We Integrate New Therapies into the Treatment of Bladder Cancer?
7:15 PM Next Steps for Immunotherapy in GU Malignancies
7:30 PM Using Genomics to Select Patients for Organ Preservation
7:45 PMDiscussion
8:00 PMAdjourn to Welcome Reception
6:00 AM Breakfast
7:00 AM Non-Invasive Monitoring of Urothelial Cancers
7:15 AM New Perspectives in PET Imaging in Prostate Cancer
7:30 AM Deep Learning in Kidney Cancer Imaging: How AI Will Revolutionize Kidney Cancer Care
7:45 AM Discussion
8:00 AM The Role of Genomic Risk in Prostate Cancer Surveillance
8:15 AM The Role of Nephrectomy in the Age of Modern Therapeutics
8:30 AM Discussion
8:45 AM Break
9:05 AM How to Choose First-line Therapy for RCC
9:20 AM Anti-tumor Activity of Small Molecule Glutaminase Inhibitors
9:35 AM Next-generation Immunotherapy in RCC
9:50 AM Discussion
10:05 AM Novel Immunoconjugates in Bladder Cancer
10:20 AM PSMA Targeted Therapies in Advanced Prostate Cancer
10:35 AMUsing Synthetic Biology to Design and Manufacture Optimized Medicines for the Treatment of Cancer
10:50 AM Discussion
11:10 AM Targeting the DNA Repair Pathway
11:25 AM Development of an Androgen Receptor PROTAC® in Prostate Cancer
11:40 AM Targeting PTEN Loss and PI3K in Prostate Cancer Therapeutics
11:55 AM Discussion
12:15 PM Adjourn
5:00 PM Hormonal Therapy: The Future of mCSPC Treatment
5:10 PM Chemotherapy is Not Dead in Prostate Cancer
5:20 PMDiscussion
5:40 PM Defining Oligometastatic Disease in Prostate Cancer
5:55 PM The Role of Treating the Primary in Metastatic Prostate Cancer
6:10 PMStereotactic Body Radiation Therapy in Oligometastatic Cancer
6:25 PMDiscussion
6:40 PMBreak
7:00 PM Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
7:15 PM Targeting the IL2 Pathway to Engage the Immune Response
7:30 PMTargeting FGFR in Bladder Cancer
7:50 PM Emerging Agent Showcase: Mirati Therapeutics
8:05 PM Discussion
8:30 PM Adjourn To Poster Reception
6:00 AM Breakfast
7:00 AM The Era of Personalized Therapy for GU Tumors
7:15 AMVEGFR TKI and PD-1/PD-L1 Combinations for First-line RCC
7:30 AMImmunotherapy in Prostate Cancer
7:45 AMImmune Checkpoint Inhibitors and Cytokine Combinations in GU Malignancies
8:00 AMCombination Immunotherapy and Radiotherapy in Bladder Cancer
8:15 AMPSMA-Targeting Radioligand Therapy in Prostate Cancer
8:30 AMDiscussion
8:50 AMBreak
9:10 AM The Relationship Between the Microbiome and GU Malignancies
9:25 AM Molecular Assessments of Resistance to Hormonal Therapies in Prostate Cancer
9:40 AM Epigenetic Modulation of Antiandrogen Resistance
9:55 AM Discussion
10:10 AM Assessing Biomarkers for Bladder Cancer
10:25 AM Non-invasive Genotyping and Stratification using Cell-free DNA
10:40 AM Utility of Circulating Tumor Cells in GU Malignancies
10:55 AM Discussion
11:10 AM Evolution of Androgen Receptor Alterations During Sequential Inhibition
11:35 AM Role of AR-V7 in Sequencing Therapeutic Agents for CRPC
11:50 AMStrategies for Targeting the Androgen Receptor Axis in Prostate Cancer
12:05 PM Apalutamide: New Approaches and Future Directions
12:20 PM Discussion
12:40 PM Adjourn
5:00 PMThe Promise of Immunotherapy in Urothelial Cancer
5:15 PMFighting Urothelial Cancer without Immunotherapy
5:30 PMDiscussion
5:50 PM The Potential of High-dose Testosterone: Re-sensitizing Patients to Hormonal Therapy
6:05 PM Addressing Neuroendocine Differentation in Prostate Cancer
6:20 PMClinical Development of PARP Inhibitors for Genitourinary Cancers
6:35 PMFuture of mTOR Inhibitors in GU Malignancies
6:50 PMDiscussion
7:10 PMWomen and Bladder Cancer: Unique Needs and Special Strategies
7:25 PM Diet and Lifestyle Modifications in Prostate Cancer
7:40 PMNew Perspectives in Non-metastatic CRPC
7:55 PM Quality of Life as an Outcome in Prostate Cancer
8:10 PMDiscussion
8:30 PMAdjourn
7:00 AMOral Abstract 1
7:15 AM Oral Abstract 2
7:30 AMOral Abstract 3
7:45 AMOral Abstract 4
8:00 AMOral Abstract 5
8:15 AMOral Abstract 6
8:30 AMMEETING CONCLUDES
